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consider severity of depression in boys as an indicator for 
antidepressant prescribing. Self-injury in girls appears to be 
utilised as a prescribing aid which is inconsistent with past 
and current revised UK NICE guidelines.
Keywords Adolescents · Depression · Antidepressants · 
SSRIs · Risk · Self-harm
Introduction
MD is a significant health problem affecting a substantial 
proportion of the adolescent population worldwide [1]. The 
estimated 12 month period prevalence of MD in teenagers 
is 7.5 % affecting around twice as many girls as boys and 
around 1 in 4 of these will have a severe clinically referable 
condition [2, 3]. The long term consequences of adoles-
cent emergent MD can include suicide, anxiety disorders, 
substance misuse and failure to both achieve education-
ally and in the work place [4]. These negative outcomes 
come at great economic cost to the UK and other national 
economies and therefore, ensuring that we manage MD 
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effectively in this age group should be a priority for public 
mental health policy and practice.
The UK NICE guidelines are one of the few focused 
and standardised recommendations available for the man-
agement of adolescent MD within Europe and indeed 
worldwide. These standards have recently undergone revi-
sion. Previous guidance promoted the use of evidence-
based psychological therapies as first line treatment, with 
SSRIs antidepressants constituting the pharmacological 
treatment of choice only if psychological therapies have 
first been tried without response, and only then, in combi-
nation with psychological therapy. The 2015 amendment 
to these guidelines allow combined SSRI and psychologi-
cal therapy first line but continue to warn against the use of 
SSRIs on their own [5]. Both state that depression should 
be moderate to severe to warrant SSRI prescribing. Given 
that this guidance has recently been reviewed, we deter-
mined whether the current management of adolescent MD 
adheres to these guidelines, either revised or in their origi-
nal form.
IMPACT is a pragmatic, multicentre randomised con-
trolled trial of adolescents with MD [6]. It is designed to 
investigate the effectiveness of three different psychologi-
cal interventions (short term psychoanalytic psychotherapy, 
cognitive behavioural therapy and manualised specialist 
clinical care) in reducing the risk of symptomatic depres-
sive relapse in the medium term 12–18 months after begin-
ning treatment. A clinical audit of NHS notes documenting 
prior treatments and medication prescribing in a sub-sam-
ple (n = 80) of participants prior to randomisation revealed 
that a marked proportion of audited cases had already been 
prescribed SSRI antidepressants prior to receiving their 
psychological intervention.
Given this apparent deviation in adherence to NICE 
guidelines, we wished to investigate the clinical ration-
ale underlying this pre-trial prescribing of antidepressants 
across the whole of the trial cohort.
Our investigations were underpinned by four principle 
hypotheses; firstly, we hypothesised that pre randomisa-
tion prescribing would be based on severity or chronicity 
of clinical presentation. Secondly, we considered whether 
prescribing was based on perceived functional impair-
ment or subjective quality of life rather than clinical signs 
and symptoms. Thirdly, we hypothesised that prescribing 
would be associated with overt risk behaviours such as self-
harm and antisocial behaviour. We reasoned that practition-
ers may perceive such hazardous behaviours to be proxy 
indices of depression severity or consider such behaviours 
as requiring rapid pharmacological management. Finally, 
given previous findings of the importance of site-specific 
effects within RCTs, we investigated the importance of 
the research site individuals derived from, both in terms of 
SSRI prescribing and sample characteristics.
Methods
Improving mood with psychoanalytic and cognitive 
therapies (IMPACT) participants
IMPACT is a pragmatic randomised control trial which 
aims to determine if one of two specialist treatments, cog-
nitive behavioural therapy (CBT) or short term psycho-
analytic psychotherapy (STPP) are superior to  a reference 
practice-based brief psychosocial intervention (BPI), at 
preventing recurrence of clinically meaningful levels of 
depressive symptoms indicating potential relapse in adoles-
cents who enter the trial with MD [6].
The study was conducted over three regions within the 
UK, East Anglia, North London and the North West of Eng-
land incorporating 16 routine Child and Adolescent Mental 
Health (CAMH) clinics. Individuals were recruited to the 
study with moderate to severe depression and aged between 
11 and 18 years. Exclusion criteria included generalised learn-
ing difficulties or a pervasive developmental disorder, preg-
nancy, currently taking another medication that may interact 
with an SSRI and being unable to stop this medication, sub-
stance misuse, primary diagnosis of Bipolar Type I disorder, 
schizophrenia or eating disorder. Of the 561 individuals who 
were referred and had baseline assessments, 470 were con-
sidered eligible with 5 later withdrawing consent, resulting in 
the recruitment of 465 overall. As part of the screening pro-
cess prior to enrolment, individuals were asked if their current 
depressive illness was a first episode or a relapse. At this point, 
demographic information including their ethnicity was col-
lected. Ethical approval was by the Cambridgeshire 2 research 
Ethics Committee, Addenbrooke’s Hospital Cambridge, UK 
and is therefore, in accordance with the ethical standards laid 
down in the 1964 Declaration of Helsinki and its later amend-
ments. Follow up was undertaken with repeated reassessments 
at up to 86 weeks after randomisation to evaluate recurrence of 
clinical level depressive symptoms. The further characterisa-
tion of the sample will be available with the publication of the 
IMPACT trial during 2016 [7].
Assessment instruments
SSRI prescribing
Antidepressant prescribing prior to entering the study was 
determined using the Child and Adolescent Service Use 
Schedule (CA-SUS) [8]. The CA-SUS is an interview-
based measure to collect data on service use and was 
designed for use within mental health populations, includ-
ing young people with depression [8]. As well as ascertain-
ing the current prescribing of psychotropic medication, it 
includes information on the individual’s accommodation, 
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education, use of hospital and community based health and 
social services, and any criminal activity or criminal justice 
sector contacts. Baseline prescribing information was avail-
able for 457 individuals of the 465 recruited to the study 
(98 %). Subsequent analyses presented here excluded par-
ticipants for whom this information is not available.
Interview measures
Schedule for affective disorders and schizophrenia 
for school aged children, present and lifetime version 
(K‑SADS‑PL) [9]
We hypothesised that SSRI prescribing may be associ-
ated with depression severity, psychiatric comorbidity or 
chronicity. This was investigated using the K-SADS-PL. 
With regard to depressive symptoms, this refers to the 22 
items used to establish the diagnosis of current depression 
in the K-SADS-PL. A score of 3 or ‘threshold’ within the 
K-SADS-PL was used to define a symptom being present. 
The comorbid diagnoses considered, according to DSM-IV 
criteria, were panic with and without agoraphobia, separa-
tion anxiety, avoidant disorder, specific phobias, general 
anxiety disorder, obsessive compulsive disorder, post-trau-
matic stress disorder, anorexia nervosa, bulimia nervosa, 
attention deficit disorder, oppositional defiant disorder, 
conduct disorder, alcohol abuse and substance and alco-
hol dependence. Psychotic symptoms were also recorded 
but individuals with a diagnosis of mania or schizophrenia 
were excluded from the study. These data were available 
for all the trial participants. Using the K-SADS-PL, the age 
of onset of depressive illness was also compared between 
groups [data available for 282 individuals (62 %)]. The 
K-SADS-PL has been shown in numerous studies to have 
high inter-rater reliability and construct validity [9].
Self‑report measures
Moods and feelings questionnaire (MFQ) [10]
The MFQ was also used to investigate if depression sever-
ity was associated with SSRI prescribing prior to randomi-
sation in the IMPACT study. It is a 33 item self-report 
measure of depressive symptoms consisting of a list of 
descriptive phrases with subjects being asked to rate their 
symptoms over the past 2 weeks. Re-test reliability and 
criterion validity are reported to be high [11]. Cronbach’s 
alpha within our study was 0.92. Items are scored from 0 to 
2 (never = 0, sometimes = 1, mostly or always = 2), yield-
ing a maximum score of 66. These data were available for 
462 out of the 465 study participants (99 %).
Health of the nation outcome scales for children 
and adolescents (HONOSCA) [12]
The HONOSCA is a measure of a young person’s total 
mental health problems. It measures 15 items includ-
ing psychiatric symptoms, behaviours, family, social and 
school functioning. Each item is scored from 0 to 4 where 
0 indicates no problems and 4 very severe problems. It is 
known to be reliable, sensitive to change and correlates 
well with the clinician’s judgement of the young person’s 
outcome [13]. HONOSCA data were available for 432 of 
the study participants (93 %).
Euroqol 5 dimension (EQ‑5D) questionnaire [14]
The EQ-5D was used to investigate whether SSRI pre-
scribing prior to randomisation in the IMPACT study was 
associated with functional impairment or quality of life. It 
is a standardised measurement of health status and health-
related quality of life. The EQ-5D-3L version was used 
which consists of five dimensions (mobility, self-care, 
usual activities, pain/discomfort and anxiety/depression), 
recorded on one of three levels (no problems = 1, some 
problems = 2, extreme problems = 3). This allowed indi-
viduals to be classified into one of 243 health states. For 
example, 11,111 representing no problems in any dimen-
sion and 33333 representing extreme problems in all five 
dimensions. A summary index value was derived by apply-
ing general population weights to each health state [15]. 
The summary scores range from 1 (perfect health) to 0 
(death) with negative scores indicating states considered to 
be worse than death. The EQ-5D was available for 436 of 
the individuals (94 %).
Modified risk taking and self‑harming inventory 
for adolescents (RTSHIA) [16]
The RTSHIA, a self-report instrument for assessing life-
time self-harm and risk taking behaviour in adolescents, 
was used to investigate whether SSRIs are prescribed to 
adolescents based on hazardous or risk-taking behaviour. 
The version used differs from the original in that 3 ques-
tions were omitted regarding risky sexual behaviour. The 
version used contained 31 items answered on a Likert scale 
(3 = many times, 2 = more than once, 1 = once, 0 = never) 
and scored as a total for hazardous behaviour ranging from 
0–93. Subscales for risk taking and self-harming were 
examined as well as the total score. Examples of questions 
that related to risk taking but not self-harm included drug 
and alcohol use, staying out late without parental knowl-
edge and actively placing oneself in risky situations such as 
cheating at school and shop lifting. Cronbach alpha scores 
for each component of the RTSHIA within our study were; 
 Eur Child Adolesc Psychiatry
1 3
total = 0.90, risk taking = 0.80, self-harming = 0.90. This 
was available for 436 individuals of those entered into the 
trial (94 %).
Behavioural checklist [17]
We also considered if antisocial behaviour may be con-
sidered a hazardous behaviour associated with prescrib-
ing. This was investigated using the Behavioural Check-
list, an 11-item screen for current symptoms of antisocial 
behaviour derived from DSM-IV criteria and converted to 
a self-report format. It is scored on a 4 point Likert scale 
(always = 3, mostly = 2, sometimes = 1, never = 0) with 
a range of 0–44. Within our study, Cronbach alpha for the 
Behavioural Checklist was 0.79. The Behavioural Checklist 
was completed by 450 of the study participants (97 %).
Statistical analysis
Many of the measures we collected were found to be non-
normally distributed. Therefore, statistical tests between 
two groups were completed using the Wilcoxen Mann–
Whitney test. The Chi-squared statistic was used to com-
pare groups based on gender, research centre and ethnicity. 
To address the issue of missing data, scores for the MFQ, 
behavioural checklist and RTSHIA total and sub-scores 
were pro-rated.
Comparison of prescribing between research centres 
was also undertaken using logistic regression. A multino-
mial logistic regression analysis was undertaken to inves-
tigate the potential effects of research centre on the popu-
lation characteristics with regard to gender, quality of life 
(EQ5D), HONOSCA score, self-harm, depression severity 
(as measured by MFQ), age and ethnicity. The relationship 
between SSRI prescribing and the predictors mentioned 
above, including research centre, was also tested using 
logistic regression analysis. Prior to this, we undertook a 
logistic regression using gender as a predictor to ascertain 
if there were gender effects on the parameters measured. 
Based on this, the model was split by gender to establish 
if there were differences in the predictors for prescribing 
between males and females.
Data were analysed using STATA Version 13 [18] for 
Windows PC.
Results
Demographics
Data regarding antidepressant prescribing prior to randomi-
sation were available for 457 out of the 465 individuals 
recruited to the IMPACT trial. Of these, 89 (19.5 %) had 
been prescribed an antidepressant before entering the trial. 
The only antidepressants that had been prescribed were 
SSRIs with the majority (83 %) taking fluoxetine, as per 
NICE guidelines. The remaining individuals were pre-
scribed citalopram (10 %) or sertraline (6 %). One individ-
ual was documented as taking an SSRI but the type of SSRI 
was not reported.
Prior to entering the study, individuals were asked if this 
was their first episode of depression. This information was 
available for 396 (85 %) of the study’s participants. There 
was no difference in any of the demographic variables (age, 
gender, ethnicity, MFQ score, age of onset of depression, 
number of depressive symptoms and number of comorbid 
disorders) measured between those for whom this informa-
tion was available and those for whom it was not. Of those 
with available information, 370 (93.4 %) reported their cur-
rent depressive illness as a first episode, the rest reporting 
a recurrence. Of the 77 individuals prescribed antidepres-
sants for whom screening information was available, 73 
reported their current depressive illness as being the first 
episode (94.8 %).
As shown in Table 1, individuals did not differ with 
regard to age, gender or ethnicity (white vs non-white) 
regardless of whether or not they were prescribed SSRIs. 
There was, however, a main effect of treatment centre, 
which will be discussed in more detail below.
Illness severity
The severity of the young person’s current depressive ill-
ness was compared between those who had been prescribed 
antidepressants before entering the IMPACT study and 
those who had not been using both observer and self-rated 
measures (Table 2).
No significant difference between groups was observed 
in self-reported depression scores, the number of inter-
view reported depressive symptoms (K-SADS PL), or 
the number of comorbid disorders associated with their 
depressive illness. There was also no difference in the age 
of onset of depressive illness obtained from the K-SADS 
PL.
Quality of life/functional impairment
Individuals who had been prescribed an SSRI reported a 
lower level of health-related quality of life than those who 
were not taking antidepressants, as measured using the 
EQ5D (Table 2). They also reported higher HONOSCA 
scores, suggesting an overall poorer mental health status 
(Table 2). Together, these findings suggest that individu-
als who had been prescribed SSRIs subjectively perceived 
themselves as more functionally impaired.
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Hazardous behaviour
Individuals who had been prescribed antidepressants had 
higher self-reported lifetime histories of hazardous behav-
iour overall, as measured using the RTSHIA (Table 2).
When analysis of hazardous behaviour was split into risk 
taking and self-harm components, there was no difference 
between the groups with regard to risk taking behaviour, 
however, those who had been prescribed antidepressants 
had higher lifetime histories of self-harming behaviours.
Antisocial behaviour
This hazard-related prescribing led us to the question of 
whether other forms of risky but non-depressive behaviour 
were also associated with antidepressant prescribing 
(Table 2). Surprisingly, individuals who had been pre-
scribed antidepressants before entering the IMPACT study 
had fewer symptoms of self-reported antisocial behaviour 
compared with those who had not been prescribed antide-
pressant medication. It should be noted, however, that the 
median scores for each group are low in both, given the 
scale range (0–33).
Prescribing differences across research centres
Prescribing rates of SSRI antidepressants differed signifi-
cantly across the three UK research centres from which 
they were recruited (Table 1). Descriptively, 30 % of indi-
viduals recruited from East Anglia had been prescribed 
Table 1  Baseline demographic 
for individuals prescribed SSRI 
antidepressants compared with 
those who were not
a Derived from K-SADS-PL—schedule for affective disorders and schizophrenia for school aged children 
present and lifetime
No SSRI prescribed 
(N = 368)
SSRI prescribed  
(N = 89)
Statistic p
Median IQR Median IQR
Age (years) 15.6 14.6–16.8 15.7 15.0–16.8 z = 1.1 0.27
Age of onset of depressiona 14.0 12.0–15.0 14.0 13.0–15.0 z = 0.1 0.89
n % n %
Research centre
 East Anglia 126 34.2 54 60.6 χ2 = 21.3 <0.000
 London 112 30.4 14 15.7
 North West 130 35.3 21 23.6
Gender
 Boys 89 24.2 27 30.3 χ2 = 1.1 0.29
Ethnicity
 White 281 76.4 74 83.1 χ2 = 1.4 0.23
Table 2  Comparison of depression severity, functional impairment, hazardous behaviour and antisocial behaviour scores between individuals 
prescribed SSRIs and those who were not
a Derived from K-SADS-PL—schedule for affective disorders and schizophrenia for school aged children present and lifetime
No SSRI prescribed 
(N = 368)
SSRI prescribed  
(N = 89)
Mann–Whitney U  
(z score)
p Effect size 
(Cohen’s d)
Median IQR Median IQR
MFQ score 46.0 38.2–54.0 50.0 42.0–55.7 1.8 0.072
No of depressive symptomsa 8.0 7.0–10.0 8.0 7.0–11.0 0.6 0.53
No of comorbid disordersa 1.0 0.0–2.0 1.0 0.0–2.0 0.6 0.54
EQ5D 0.7 0.4–0.8 0.4 0.3–0.7 2.6 0.008 −0.32
HONOSCA 18.0 14.0–22.0 20.0 16.1–24.0 2.3 0.024 0.24
RTSHIA hazardous behaviour total 18.0 9.0–29.0 20.0 11.8–33.2 2.0 0.043 0.25
RTSHIA—risk taking 5.0 2.0–9.0 5.0 1.0–11.2 0.05 0.96
RTSHIA—self-harm 12.0 5.0–21.0 15.5 7.0–24.2 2.19 0.028 0.28
Antisocial behaviour 3.0 1.0–5.0 2.0 0.0–4.0 2.3 0.021 −0.31
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SSRIs prior to entering the study, compared with 11.1 
and 13.9 % from London and the North West of England, 
respectively. Participants in East Anglia were, therefore, 
2.7 (z = 3.4, p = 0.001) times more likely to be prescribed 
an SSRI compared with those recruited from the other two 
research centres.
These prescribing differences, however, did not explain 
the observed relationship between medication prescribing, 
quality of life/functional impairment and risky behaviour 
(Table 3). The pattern of quality of life, self-harming and 
antisocial behaviour scores were the same across research 
centres with the group who had been prescribed SSRIs 
prior to entering the study exhibiting lower EQ-5D scores 
(poorer health-related quality of life), higher HONOSCA 
scores (poorer overall mental health outcomes), higher 
self-harm/suicidality levels and lower antisocial behaviour 
levels, compared with those who had not been prescribed 
antidepressant medication.
We tested for potential effects of centre on sample char-
acteristics using a multinomial logistic regression (Supple-
mentary Table 1). This showed that individuals recruited 
from London and the North West displayed lower self-harm 
scores compared with those recruited from East Anglia 
[median score (IQR): East Anglia: 16.0 (9.0–26.0), Lon-
don: 13.0 (5.0–21.0), North West: 10.0 (4.0–20.5)]. Indi-
viduals from London were also slightly older [median age 
(IQR): East Anglia: 15.5 (14.7–16.3) years, London: 16.1 
(14.8–17.2) years, North West: 15.6 (14.6–16.7) years] 
and more likely to be of a non-Caucasian ethnicity (East 
Anglia: 90 % Caucasian, London: 53 % Caucasian, North 
West: 84 % Caucasian). Adolescents from the North West 
had significantly lower HONOSCA scores compared with 
the East Anglian population [median score (IQR): East 
Anglia 19.2 (16.0–24.9), London: 20.0 (14.4–25.8), North 
West: 17.0 (13.0–21.3)].
Gender differences in SSRI prescribing predictors
A logistic regression using gender as an interaction term 
allowed for any potential effects of gender on each of the 
univariates predicting SSRI prescribing to be investigated 
(Supplementary Table 2). Depression severity (as measured 
by MFQ) was added to the model as the difference between 
the two groups approached significance. Age was also 
added to the model in case this was shown to be a prescrib-
ing predictor when other interactions were controlled for. 
This showed that SSRI prescribing appeared to be more 
likely in girls with higher self-harm scores and boys with 
greater depressive symptoms (as measured by MFQ). 
This was confirmed by a further logistic regression analy-
sis examining for main effects and interactions between 
SSRI prescribing and the possible predictors; quality 
of life, total mental health problems (as measured by the 
HONOSCA), self-harm, antisocial behaviour, depression 
severity, research centre and ethnicity. Given the findings 
from our first model, this analysis was undertaken for boys 
and girls separately and the results are presented in Table 4. 
They confirmed that the main predictor for prescribing dif-
fered based on gender. For girls, prescribing was associated 
with a history of self-harming behaviour. In contrast, pre-
scribing for boys was associated with depression severity 
at randomisation. The area boys were recruited from also 
appeared to play a role as to whether they were prescribed 
SSRIs or not, they were more likely to be prescribed anti-
depressants if they came from East Anglia as opposed to 
London or the North West of the UK.
Discussion
We set out to explore the clinical characteristics that may 
account for the prescribing of antidepressants to adoles-
cents with moderate to severe depression prior to enter-
ing the IMPACT study. To do this, we studied the baseline 
clinical characteristics of individuals including the severity/
chronicity of depression, quality of life/functional impair-
ment, self-harming/suicidality and other risk related antiso-
cial behaviours.
The majority of individuals (>90 %) were experienc-
ing their first episode of depression and did not report at 
recruitment receiving any formal psychological treatment 
before entering the trial. Therefore, at least 19 % of the 
study population received an SSRI without a concurrent 
psychological treatment.
Table 3  Relationship between SSRI prescribing, EQ5D, HONOSCA, hazardous behaviour, self-harm and antisocial behaviour across research 
centres
East Anglia London North West
No SSRI mean (SD) SSRI mean (SD) No SSRI mean (SD) SSRI mean (SD) No SSRI mean (SD) SSRI mean (SD)
EQ5D 0.59 (0.25) 0.48 (0.25) 0.56 (0.30) 0.48 (0.30) 0.59 (0.27) 0.53 (0.26)
HONOSCA 18.9 (5.2) 19.9 (5.6) 18.8 (6.5) 22.9 (6.6) 17.1 (6.4) 17.2 (5.7)
RTSHIA—self-harm 17.1 (10.8) 17.5 (11.1) 13.1 (9.8) 15.5 (10.6) 11.2 (9.7) 16 (13.7)
Antisocial behaviour 3.5 (3.2) 2.2 (2.3) 3.8 (3.3) 3.4 (3.3) 3.2 (3.4) 2.6 (2.7)
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So what are the clinical characteristics underlying the 
prior antidepressant prescribing in those adolescents with 
MD recruited subsequently to the trial? Within the total 
population, significant differences were noted in non-
depressive symptoms and behaviours: those who had been 
prescribed SSRIs prior to entering the IMPACT study 
reported a reduced quality of life, higher subjective total 
mental health problems and higher levels of self-harm 
compared with those not prescribed. Unexpectedly, young 
people who had been prescribed SSRIs also reported lower 
antisocial behaviour symptoms. Perhaps, low antisocial 
behaviour in a presumed depressed adolescent is a con-
tributory factor to SSRI prescribing. However, it should be 
noted that scores were low across the cohort, making inter-
pretation of this result unclear.
We also identified significant differences between SSRI 
prescribing and the area within the UK the young person 
came from. Individuals from East Anglia were more than 
twice as likely to receive antidepressants compared with 
those from London or the North West of England, as well 
as being more likely to report greater life-time histories of 
self-harm. In an attempt to understand how the differences 
we found between individuals who had and had not been 
prescribed SSRIs interacted, we included all the variables 
where differences were seen within a logistic regression 
model predicting SSRI prescribing The results suggested 
that the rationale underlying SSRI prescribing in adoles-
cents differed based on gender; self-harm being the main 
predicting factor for SSRI prescribing in girls, whilst sever-
ity of depressive illness predicted prescribing in boys.
If, as it seems, NICE guidelines, within the UK, are not 
being systematically followed, the question must therefore 
be why not? It is possible that issues such as low diagnos-
tic accuracy, a lack of familiarity with current guidelines, 
insufficiently available adequately trained adolescent men-
tal health practitioner and inadequate psychological ser-
vices available in secondary and tertiary care [19], may all 
compromise the chances of such guidance being followed. 
It is also possible that some psychiatrists disagree with 
NICE guidelines so chose not to follow them.
It may be argued that in a number of adolescents with 
severe depression, SSRIs should be the treatment of first 
choice with psychological therapies added, as remission 
ensues to aid recovery and prevent relapse [20]. However, 
the evidence for the effectiveness of SSRIs is derived from 
studies where they have been prescribed based on depres-
sive symptoms and severity [20, 21]. Little is known 
regarding their effectiveness when prescribed on the basis 
of non-depressive hazardous risk behaviour and it is pos-
sible that they may be less effective in this population.
Why do the clinical characteristics for prescribing appear 
to differ between boys and girls? One possibility is that as 
depression is more common in girls, perhaps, clinicians are 
wary about prescribing for these symptoms alone and see 
self-harming behaviour (more common in girls [22, 23]) as 
a marker of high risk warranting SSRIs. It is possible that 
Table 4  Logistic regression 
analysis, demonstrating 
the relationship between 
quality of life, self-harm, 
antisocial behaviour and 
centre as predictors for SSRI 
prescribing at baseline
a Compared with East Anglia
Odds ratio S.E. z p 95 % C.I.
Girls
 EQ5D—quality of life 0.50 0.63 −1.10 0.27 −1.92–0.54
 HONOSCA—total mental health problems 1.05 0.03 1.57 0.12 −0.01–0.11
 RTSHIA—self-harm 1.03 0.02 2.00 0.045 0.001–0.065
 Behavioural checklist—antisocial behaviour 0.89 0.06 −1.78 0.076 −0.24–0.01
 MFQ—depression severity 0.99 0.02 −0.71 0.48 −0.052–0.024
 Age 1.17 0.13 1.19 0.23 −0.10–0.41
 Research Centre: Londona 0.44 0.46 −1.77 0.076 −1.70–0.09
 Research Centre: North Westa 0.61 0.37 −1.35 0.18 −1.23–0.23
 Ethnicity 1.25 0.45 0.50 0.61 −0.65–1.10
Boys
 EQ5D—quality of life 0.64 1.10 −0.41 0.68 −2.60–1.71
 HONOSCA—total mental health problems 1.00 0.05 0.10 0.92 −0.09–0.10
 RTSHIA—self-harm 0.95 0.03 −1.39 0.17 −0.12–0.02
 Behavioural checklist—antisocial behaviour 0.86 0.09 −1.67 0.095 −0.34–0.03
 MFQ—depression severity 1.07 0.03 2.04 0.042 0.002–0.13
 Age 1.32 0.18 1.53 0.13 −0.08–0.63
 Research Centre: Londona 0.12 0.86 −2.52 0.012 −3.84 to −0.48
 Research Centre: North Westa 0.15 0.66 −2.91 0.004 −3.22 to −0.63
 Ethnicity 0.78 0.75 −0.34 0.74 −1.72–1.08
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as fewer boys present with depression, clinicians feel they 
require a lower threshold of risk to prescribe.
Limitations
The main limitation of this study is that we have no clini-
cal measurements available regarding illness severity and 
quality of life when assessed by the clinicians who pre-
scribed prior to ranodmisation. Therefore, it is theoretically 
possible that SSRI cases were more severely depressed 
when first assessed as suffering from MD than their non-
SSRI counterparts, when seen before entering the trial. It 
should be noted that a case-note audit of 80 participating 
individuals from one of the clinics involved in the study 
showed that 75 % of the cases had been prescribed medi-
cation for less than 3 months prior to randomisation, and 
more than half of these had received medication for less 
than 1 month. Although it is possible that there may be 
some signs of improvement this early on in treatment [24], 
we believe that this would be unlikely to change the out-
come of the study. Indeed, we argue that if this were the 
case, assessment at the time of prescribing would lead to 
greater effects in terms of the differences seen. It should 
be noted that the measurements of risk behaviour and self-
harm are based over the lifetime and are, therefore, unlikely 
to be susceptible to change within this time frame.
We do, however, accept that our study should be consid-
ered as correlative rather than indicative.
We believe that the data presented reflects the poten-
tial rationale for prescribing SSRIs prior to psychological 
therapy. When asked prior to randomisation if they had 
received any previous psychological therapy or counsel-
ling, only nine individuals (2 %) reported that they had and 
only three of these were prescribed SSRIs. However, fur-
ther questioning by trial therapists suggests that although 
participants do not appear to have received any evidence-
based psychological therapy, a number have had access to 
certain types of talking therapy including counselling ser-
vices. This raises the possibility for poor reliability with 
regard to the recall of previous therapy.
We recognise that some aspects of our findings may be 
UK specific and our findings would benefit from replica-
tion within other international healthcare systems. How-
ever, our study uses internationally recognised methods for 
recruiting adolescents with MDD and therefore, we believe 
our sample to be comparable with patient groups through-
out Europe and worldwide.
It is also possible that there are characteristics of the 
individuals or their environmental context including family 
history of mental illness that may account for these find-
ings. Finally, this is a relatively small sample of adolescent 
patients and is particularly biased towards females, mean-
ing that our findings regarding the prescribing rationale for 
boys may be associated with a type one or type two error. 
The participants were also recruited and consented to take 
part in a randomised controlled trial and therefore, may not 
be entirely representative of the general population of ado-
lescents with depression. As this may affect the generaliz-
ability of our study, these findings require replication in an 
independent study.
Currently, we conclude that pragmatic SSRI prescribing 
in the NHS may be based on depressive severity for boys 
but overt hazardous behaviour for girls. This suggests that 
there may be greater adherence to NICE guidelines by cli-
nicians treating boys as opposed to girls but this remains to 
be established. In addition, it appears that prescribing dif-
fers in distinct areas of the country. The NICE guidelines 
have recently been reviewed, however, we believe that 
before they can be seriously implemented, it is necessary 
to understand how adolescent MD is currently managed in 
everyday clinical practice.
Clinical implications
• The NICE guidance for the treatment of adolescent MD 
has recently been reviewed, however, to aid our under-
standing of the optimal management of this debilitating 
condition, we need to be aware of the reasons clinicians 
depart from these guidelines. Trial evidence and clini-
cal guidelines should be considered together along with 
a better understanding of what takes place currently in 
clinical practice.
• Positive reasons should be recorded in the notes for pre-
scribing SSRIs along with any previous failure of an 
adequately given psychological treatment. These might 
explain why clinicians in the UK seem not to be adher-
ing to NICE guidelines.
• Self-harming behaviour should not on its own prompt 
SSRI prescribing. Instead, prescribing is warranted 
when suicidality and risk behaviour is combined with 
moderate to severe depressive symptoms.
• Different reasons may be used for prescribing SSRIs for 
girls and boys, despite there being no evidence that this 
is correct practice.
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